We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Lixisenatide (GLP-1 receptor agonist)
An FDA-approved once-daily GLP-1 receptor agonist (brand Adlyxin in the US, Lyxumia elsewhere) for type 2 diabetes. Honest appraisal: a short-acting, prandial GLP-1 with modest efficacy — it lowers HbA1c by roughly half a percentage point and produces only small weight loss, with its main strength being post-meal glucose control. Its cardiovascular-outcomes trial (ELIXA) was NEUTRAL: no increase but also no reduction in cardiovascular events. It is a real prescription medicine, not a supplement, and is now largely superseded by stronger weekly GLP-1s (semaglutide, dulaglutide). It is not auto-recommended.
Prescription medication — not a dietary supplement
Lixisenatide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Lixisenatide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2010–2026 with a typical study size of 634 participants.
Based on 164 studies · 55 meta-analyses · 90 RCTs · 634 total participants
Confidence
High confidenceBy outcome
Scored 'Moderate' (5) because large phase-3 RCTs and meta-analyses prove real but modest glycemic efficacy, while its cardiovascular outcomes trial was neutral and weight loss is minimal — weaker than other GLP-1 agonists.
95 randomised trials
94% were about Lixisenatide in an audit of 50 of them
Every randomised or controlled trial of Lixisenatide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
8 trials ongoing or recruiting · 58 completed on ClinicalTrials.gov
26 of the completed trials have posted results
Registered trials show research momentum for Lixisenatide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Lixisenatide is a short-acting, once-daily analogue of the gut incretin hormone GLP-1 (glucagon-like peptide-1).
It is a prescription drug, NOT a dietary supplement: marketed as Adlyxin (US) and Lyxumia (EU and elsewhere), given by once-daily subcutaneous injection (20 µg) for type 2 diabetes, and developed by Sanofi (first global approval 2013).
Mechanistically it activates the GLP-1 receptor, which stimulates glucose-dependent insulin secretion, suppresses glucagon, and — most distinctively for a short-acting agent — markedly delays gastric emptying.
Because its receptor activation is short-lived (prandial) rather than continuous, lixisenatide lowers POST-MEAL (postprandial) glucose more than fasting glucose, which sets it apart from longer-acting GLP-1s like liraglutide and semaglutide. The honest evidence picture is one of MODEST efficacy.
The phase-3 GetGoal program (a series of randomized placebo-controlled trials as monotherapy and as add-on to oral agents, pioglitazone, or basal insulin) consistently showed HbA1c reductions of roughly -0.4% to -0.7% versus placebo, pronounced reductions in 2-hour postprandial glucose, and only small weight changes (typically about -0.4 to -0.9 kg, or no weight gain).
A pooled GetGoal meta-analysis found a 76-week HbA1c reduction of -0.41% and a body-weight reduction of only -0.40 kg. Head-to-head (GetGoal-X) it was non-inferior to twice-daily exenatide on HbA1c with better GI tolerability.
The cardiovascular-outcomes trial ELIXA (6,068 patients with type 2 diabetes and a recent acute coronary syndrome) is the key honesty point: lixisenatide was NEUTRAL — non-inferior but NOT superior to placebo for major cardiovascular events (hazard ratio 1.02, 95% CI 0.89-1.17), with no reduction in heart failure hospitalization or death.
This contrasts with the cardiovascular BENEFIT later shown for liraglutide, semaglutide, and dulaglutide. Class meta-analyses that pool all GLP-1 cardiovascular-outcome trials show an overall ~12% MACE reduction, but lixisenatide itself contributed a neutral result.
The most common adverse effects are gastrointestinal (nausea, vomiting), and a thyroid C-cell tumor class warning and pancreatitis caution apply as for other GLP-1 receptor agonists.
Overall, lixisenatide is a real, approved drug with genuine but modest glycemic efficacy, a neutral cardiovascular profile, and limited weight benefit — and it has been largely superseded in practice by more potent once-weekly GLP-1 agonists.
A short-acting, prandial analogue of the incretin hormone GLP-1 that binds and activates the GLP-1 receptor. Unlike continuous long-acting GLP-1s, its receptor activation is short-lived — the upstream target that drives all downstream effects, biased toward post-meal glucose.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk.
Strongly slows gastric emptying — the dominant mechanism behind its pronounced postprandial-glucose lowering, and also the reason nausea is its most common adverse effect.
Acts on appetite circuits to reduce food intake, but as a short-acting agent the weight effect is small — typically minor weight loss or prevention of weight gain rather than the substantial loss seen with potent weekly GLP-1s.
How Lixisenatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid — GLP-1 class warning for thyroid C-cell tumors.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Not recommended — limited data; no dose adjustment needed for mild-to-moderate impairment but monitor.
Contraindicated — discontinue before a planned pregnancy.
Combining with basal insulin or sulfonylureas raises hypoglycemia risk; the clinician typically reduces those agents. Lixisenatide alone is low-hypoglycemia (glucose-dependent action).
Marked delay of gastric emptying can change the absorption of co-administered oral drugs (e.g. oral contraceptives, antibiotics); clinician monitoring and timing adjustments advised.
Do not combine with another GLP-1 agonist (e.g. liraglutide, dulaglutide, semaglutide, exenatide) — additive risk with no added benefit.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Clinician reduces background insulin/sulfonylurea dose; monitor blood glucose
Tip: Rotate injection sites; report rash, swelling, or systemic allergic symptoms
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Lixisenatide has an evidence score of 5/10 — moderate evidence based on 164 indexed studies, including 6 meta-analyses. An FDA-approved once-daily GLP-1 receptor agonist (brand Adlyxin in the US, Lyxumia elsewhere) for type 2 diabetes. Honest appraisal: a short-acting, prandial GLP-1 with modest efficacy — it lowers HbA1c by roughly half a percentage point and produces only small weight loss, with its main strength being post-meal glucose control. Its cardiovascular-outcomes trial (ELIXA) was NEUTRAL: no increase but also no reduction in cardiovascular events. It is a real prescription medicine, not a supplement, and is now largely superseded by stronger weekly GLP-1s (semaglutide, dulaglutide). It is not auto-recommended. Representative study: PMID 31422062.
Dosing for Lixisenatide: Prescription-only, clinician-directed. Subcutaneous 20 µg once daily within the hour before the first meal of the day, after a 10 µg starting dose for 14 days. DO NOT self-dose. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take Lixisenatide is in the morning. It can be taken on an empty stomach. Given once daily by subcutaneous injection within the hour before the first meal of the day (prandial dosing), because its main benefit is blunting the post-meal glucose rise.
Lixisenatide should be used with caution — talk to a healthcare provider before taking it. Reported side effects include acute pancreatitis, symptomatic hypoglycemia (mainly with insulin/sulfonylurea), nausea. How often they occur is not established for all of them. Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 class C-cell tumor warning; Multiple Endocrine Neoplasia syndrome type 2 (MEN2); Prior serious hypersensitivity to lixisenatide or any GLP-1 receptor agonist.
What side effects does Lixisenatide have?Don't take this if…
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Dulaglutide
Too few graded studiesAn FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is a prescription drug, not a supplement, and is never auto-recommended.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 164 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research